Cargando…
The challenges of COVID‐19 Delta variant: Prevention and vaccine development
Several SARS‐CoV‐2 variants have emerged since the pandemic, bringing about a renewed threat to the public. Delta variant (B.1.617.2) was first detected in October 2020 in India and was characterized as variants of concern (VOC) by WHO on May 11, 2021. Delta variant rapidly outcompeted other variant...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661803/ https://www.ncbi.nlm.nih.gov/pubmed/34909755 http://dx.doi.org/10.1002/mco2.95 |
_version_ | 1784613390522515456 |
---|---|
author | He, Xuemei He, Cai Hong, Weiqi Zhang, Kang Wei, Xiawei |
author_facet | He, Xuemei He, Cai Hong, Weiqi Zhang, Kang Wei, Xiawei |
author_sort | He, Xuemei |
collection | PubMed |
description | Several SARS‐CoV‐2 variants have emerged since the pandemic, bringing about a renewed threat to the public. Delta variant (B.1.617.2) was first detected in October 2020 in India and was characterized as variants of concern (VOC) by WHO on May 11, 2021. Delta variant rapidly outcompeted other variants to become the dominant circulating lineages due to its clear competitive advantage. There is emerging evidence of enhanced transmissibility and reduced vaccine effectiveness (VE) against Delta variant. Therefore, it is crucial to understand the features and phenotypic effects of this variant. Herein, we comprehensively described the evaluation and features of Delta variant, summarized the effects of mutations in spike on the infectivity, transmission ability, immune evasion, and provided a perspective on efficient approaches for preventing and overcoming COVID‐19. |
format | Online Article Text |
id | pubmed-8661803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86618032021-12-10 The challenges of COVID‐19 Delta variant: Prevention and vaccine development He, Xuemei He, Cai Hong, Weiqi Zhang, Kang Wei, Xiawei MedComm (2020) Perspectives Several SARS‐CoV‐2 variants have emerged since the pandemic, bringing about a renewed threat to the public. Delta variant (B.1.617.2) was first detected in October 2020 in India and was characterized as variants of concern (VOC) by WHO on May 11, 2021. Delta variant rapidly outcompeted other variants to become the dominant circulating lineages due to its clear competitive advantage. There is emerging evidence of enhanced transmissibility and reduced vaccine effectiveness (VE) against Delta variant. Therefore, it is crucial to understand the features and phenotypic effects of this variant. Herein, we comprehensively described the evaluation and features of Delta variant, summarized the effects of mutations in spike on the infectivity, transmission ability, immune evasion, and provided a perspective on efficient approaches for preventing and overcoming COVID‐19. John Wiley and Sons Inc. 2021-10-19 /pmc/articles/PMC8661803/ /pubmed/34909755 http://dx.doi.org/10.1002/mco2.95 Text en © 2021 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Perspectives He, Xuemei He, Cai Hong, Weiqi Zhang, Kang Wei, Xiawei The challenges of COVID‐19 Delta variant: Prevention and vaccine development |
title | The challenges of COVID‐19 Delta variant: Prevention and vaccine development |
title_full | The challenges of COVID‐19 Delta variant: Prevention and vaccine development |
title_fullStr | The challenges of COVID‐19 Delta variant: Prevention and vaccine development |
title_full_unstemmed | The challenges of COVID‐19 Delta variant: Prevention and vaccine development |
title_short | The challenges of COVID‐19 Delta variant: Prevention and vaccine development |
title_sort | challenges of covid‐19 delta variant: prevention and vaccine development |
topic | Perspectives |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661803/ https://www.ncbi.nlm.nih.gov/pubmed/34909755 http://dx.doi.org/10.1002/mco2.95 |
work_keys_str_mv | AT hexuemei thechallengesofcovid19deltavariantpreventionandvaccinedevelopment AT hecai thechallengesofcovid19deltavariantpreventionandvaccinedevelopment AT hongweiqi thechallengesofcovid19deltavariantpreventionandvaccinedevelopment AT zhangkang thechallengesofcovid19deltavariantpreventionandvaccinedevelopment AT weixiawei thechallengesofcovid19deltavariantpreventionandvaccinedevelopment AT hexuemei challengesofcovid19deltavariantpreventionandvaccinedevelopment AT hecai challengesofcovid19deltavariantpreventionandvaccinedevelopment AT hongweiqi challengesofcovid19deltavariantpreventionandvaccinedevelopment AT zhangkang challengesofcovid19deltavariantpreventionandvaccinedevelopment AT weixiawei challengesofcovid19deltavariantpreventionandvaccinedevelopment |